Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: A comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients

Catheterization and Cardiovascular Interventions

Volumn 77, Issue 3, 2011, Pages 343-355

  Hakeem, Abdul ^a   Helmy, Tarek ^a   Munsif, Siddharth ^a   Bhatti, Sabha ^a   Mazraeshahi, Reza ^a   Cilingiroglu, Mehmet ^a   Effat, Mohamed ^a   Leesar, Massoud ^a   Arif, Imran ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

bypass grafts; coronary; drug eluting stents; percutaneous coronary intervention

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN;

ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; COCHRANE LIBRARY; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG USE; EMBASE; FOLLOW UP; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTERVENTION STUDY; MEDLINE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SAPHENOUS VEIN GRAFT; STENT THROMBOSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

ANGIOPLASTY, BALLOON, CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; GRAFT OCCLUSION, VASCULAR; HUMANS; METALS; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT SELECTION; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SAPHENOUS VEIN; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79951927908     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22720     Document Type: Article

References (50)

1. Eagle KA, Guyton RA, Davidoff R, et al. American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypasses graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2004; 110: e340-e437.
2. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR,. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28: 616-626. (Pubitemid 26288642)
3. Baim DS,. Percutaneous treatment of saphenous vein graft disease: The ongoing challenge. J Am Coll Cardiol 2003; 42: 1370-1372. (Pubitemid 37267274)
4. Motwani JG, Topol EJ,. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916-931. (Pubitemid 28113931)
5. Nwasokwa ON,. Coronary artery bypass graft disease. Ann Intern Med 1995; 123: 528-545.
6. Coolong A, Baim DS, Kuntz RE, O'Malley AJ, Marulkar S, Cutlip DE, Popma JJ, Mauri L,. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 2008; 117: 790-797. (Pubitemid 351640680)
7. de Feyter PJ, van Suylen RJ, de Jaegere PP, et al. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 1993; 21: 1539-1549. (Pubitemid 23170424)
8. de Jaegere PP, van Domburg RT, Feyter PJ, Ruygrok PN, van der Giessen WJ, van den Brand MJ, Serruys PW,. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996; 28: 89-96. (Pubitemid 26266627)
9. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB III, Werner JA, Bailey SR, Overlie PA, Fenton SH, Brinker JA, Leon MB, Goldberg S,. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts: Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337: 740-747. (Pubitemid 27417973)
10. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G,. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts. Results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007; 50: 261-267. (Pubitemid 47039289)
11. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S,. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions: The SOS (stenting of saphenous vein grafts) trial. J Am Coll Cardiol 2009; 53: 919-928.
12. Jeger RV, Schneiter S, Kaiser C, Bonetti PO, Brunner-La Rocca H, Handke M, Osswald S, Buser PT, Pfisterer ME,; BASKET Investigators. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology 2009; 112: 49-55.
13. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1. (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). 2008. Available from.
14. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
15. Higgins JPT, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. (Pubitemid 34746062)
16. Higgins JPT, Thompson SG, Deeks J, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560. (Pubitemid 37088507)
17. Ge L, Lakovou L, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, Montorfano M, Michev L, Airoldi F, Carlino M, Corvaja N, Colombo A,. Treatment of saphenous vein graft lesions with drug eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005; 45: 989-994. (Pubitemid 40432427)
18. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR,. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005; 66: 507-511. (Pubitemid 41779016)
19. Chu W, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, Alexieva-Fournadjiev J, Pichard AD, Satler LW, Kent KM, Lindsay J, Waksman R,. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006; 97: 34-37. (Pubitemid 41828119)
20. Wilson BH, Humphrey AD, Cedarholm JD, Elliot CM, Harber RH, Kowalchuk GT, Rinaldi MS, Simonton CA,. Drug-eluting stents are no better than bare metal in vein graft: Results from the strategy transcatheter evaluation of new therapies (STENT) group. J Am Coll Cardiol 2007; 41B: 2802-2803.
21. Ellis SG, David K, Kereiakes DJ, Pichard A, Huber K, Resnic F, Yakubov S, Callahan K, Borgman M, Cohen SA,. Utility of sirolimus-eluting cypher™ stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses. J Invasive Cardiol 2007; 19: 404-409. (Pubitemid 47509462)
22. Latib A, Ferri L, Cosgrave J, Godino C, Romagnoli E, Ielasi A, Chieffo A, Airoldi F, Montorfano M, Colombo A,. A comparison of the long-term (2 year) safety and efficacy of drug-eluting and bare-metal stent implantation in saphenous vein grafts. Eur Heart J 2008; 29 (Suppl): 455-456.
23. Okabe T, Lindsay J, Buch AN, Steinberg DH, Roy P, Slottow TLP, Smith K, Torguson R, Xue Z, Satler LF, Kent KM, Pichard AD, Weissman NJ, Waksman R,. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol 2008; 102: 530-534.
24. Baldwin DE, Trost JC, Abbott J, Vlachos H, Slater JN, Beohar N, Williams DO,. A comparison of drug-eluting and bare-metal stents for saphenous vein graft lesions: A report from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2008; 51 (Suppl): B23-B98.
25. Wöhrle J, Nusser T, Kestler HA, Kochs M, Hombach V,. Comparison of the slow-release polymerbased paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007; 96: 70-76. (Pubitemid 46233208)
26. Bansal D, Muppidi R, Singla S, Sukhija R, Zarich S, Mehta JL, Sachdeva R,. Percutaneous intervention on the saphenous vein bypass grafts-Long-term outcomes. Catheter Cardiovasc Interv 2008; 71: 58-61. (Pubitemid 351158347)
27. Hoffmann R, Pohl T, Köster R, Blindt R, Boeckstegers P, Heitzer T,. Implantation of paclitaxel-eluting stents in saphenous vein grafts: Clinical and angiographic follow-up results from a multicentre study. Heart 2007; 93: 331-334. (Pubitemid 46579523)
28. Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DM, Cuomo LJ, Wong SC,. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 2007; 20: 458-465. (Pubitemid 350179467)
29. Bair TL, Muhlestein JB, May HT, Horne BD, Li Q, Anderson JL, Lappe DL,. Use of drug-eluting stents in saphenous vein graft lesions. J Am Coll Cardiol 2008; 51 (S1): A381.
30. Gioia G, Benassi A, Mohendra R, Chowdhury K, Masood I, Matthai W,. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 2008; 72: 13-20. (Pubitemid 352008974)
31. van Twisk PH, Daemen J, Kukreja N, van Domburg RT, Serruys PW,. Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts. Eurointervention 2008; 4: 311-317.
32. O'Neal KR, Safley DM, Kennedy KF, House JH, Grantham JA, Rutherford BD, Marso SP,. There is no increased risk of death following placement of a drug-eluting stent in a saphenous vein graft. J Am Coll Cardiol 2008; 51 (Suppl): B23-B98.
33. Ramana RK, Ronan A, Cohoon K, Homan D, Sutherland J, Steen L, Liu J, Loeb H, Lewis BE,. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv 2008; 6: 886-893. (Pubitemid 351951305)
34. Kaplan S, Barlis P, Kiris A, Dimopoulos K, Celik S, Di Mario C,. Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. Acute Cardiac Care 2008; 10: 88-92. (Pubitemid 351883440)
35. Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, Varani E, Piovaccari G, Menozzi A, Percoco G, Benassi A, Rusticali G, Marzaroli P, Guastaroba P, Grilli R, Maresta A, Antonio Marzocchi A,. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna Registry). Am J Cardiol 2008; 101: 947-952.
36. Assali A, Raz Y, Vaknin-Assa H, Ben-Dor I, Brosh D, Teplitsky I, Fuchs S, Kornowski R,. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. Eurointervention 2008; 4: 108-114.
37. Applegate RJ, Sacrinty M, Kutcher M, Santos R, Gandhi S, Little W,. Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis. Catheter Cardiovasc Interv 2008; 72: 7-12. (Pubitemid 352013502)
38. Lozano I, García-Camarero T, Arrillo P, Baz JA, de la Torre JM, Lõpez-Palop R, Pinar E, Salvatella N, Avanzas P, Valdés M,. Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results. Rev Esp Cardiol 2009; 62: 39-47.
39. Nair SB, Chacko S, Clarke B, El-Omar M, Ordoubadi F, Fraser D, Mahadevan V, Khattar RS, Neyses L, Mamas M,. Comparison of drug eluting stents and bare metal stents in saphenous vein graft PCI; a single centre experience. Eur Heart J 2009; 30 (Suppl): 253.
40. Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw B, Humphrey A, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Simonton C,. Late "Catch-up" in target vessel revascularization with drug eluting stents vs bare metal stents in saphenous vein graft intervention: Two year results from the strategic transcatheter evaluation of new therapies (STENT) group. Am J Cardiol 2009; 104 (Suppl); 13D.
41. Shishehbor MH, Hawi R, Singh IM, Tuzcu EM, Bhatt DL, Ellis SG, Kapadia SR,. Drug-eluting versus bare-metal stents for treating saphenous vein grafts. Am Heart J. 2009; 158: 637-643.
42. Goswami NJ, Gaffigan M, Berrio G, Plessa AL, Pfeiffer AM, Markwell SJ, Mishkel GJ,. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: Results from the prairie "real world". Stent Registry. Catheter Cardiovasc Interv 2010; 75: 93-100.
43. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW,. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
44. Nayak AK, Kawamura A, Nesto RW, et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J. 2006; 70: 1026-1029. (Pubitemid 44161740)
45. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-1264. (Pubitemid 43866610)
46. Bossi I, Klersy C, Black AJ, et al. In-stent restenosis: Long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol 2000; 35: 1569-1576. (Pubitemid 30307502)
47. Walters DL, Harding SA, Walsh CR, et al. Acute coronary syndrome is a common clinical presentation of in-stent restenosis. Am J Cardiol 2002; 89: 491-494. (Pubitemid 34178555)
48. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B,; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: e1-e121. (Pubitemid 43005195)
49. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ,. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials. Circulation 2002; 106: 3063-3067. (Pubitemid 35440289)
50. Agostoni P, Vermeersch P, Semeraro O, Verheye S, Van Langenhove G, Van den Heuvel P, Convens C, Van den Branden F, Bruining N,. Intravascular ultrasound comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent] trial). Am J Cardiol 2007; 100: 52-58. (Pubitemid 46970699)